Reference drugs for triple combination test drug in Russia [Design Issues]
Сomprehensive article:
doi:https://doi.org/10.30895/1991-2919-2019-9-1-14-27
Over the past 10 years some new fixed combinations containing previously registered drugs were approved for use in the Russian Federation based on the results of a single clinical study of bioequivalence in healthy volunteers versus registered monocomponent reference drug. However, this practice does not fully comply with current Russian legislation.
A. V. Dobrovolskiy - Scientific Centre for Expert Evaluation of Medicinal Products ("FGBU")
doi:https://doi.org/10.30895/1991-2919-2019-9-1-14-27
Over the past 10 years some new fixed combinations containing previously registered drugs were approved for use in the Russian Federation based on the results of a single clinical study of bioequivalence in healthy volunteers versus registered monocomponent reference drug. However, this practice does not fully comply with current Russian legislation.
A. V. Dobrovolskiy - Scientific Centre for Expert Evaluation of Medicinal Products ("FGBU")
Complete thread:
- Reference drugs for triple combination test drug in Russia Beholder 2019-11-13 12:47 [Design Issues]
- Reference drugs for triple combination test drug in Russia PharmCat 2019-11-13 21:25
- Reference drugs for triple combination test drug in Russia Yura 2019-11-14 09:24
- Reference drugs for triple combination test drug in Russia Beholder 2019-11-14 10:55
- Reference drugs for triple combination test drug in Russia Beholder 2019-11-14 10:51
- Reference drugs for triple combination test drug in Russia Mikalai 2019-11-15 13:36
- OT: Speak with the regulator Helmut 2019-11-15 13:45
- Reference drugs for triple combination test drug in Russia PharmCat 2019-11-15 20:07
- Reference drugs for triple combination test drug in Russia mittyri 2019-11-15 23:29
- Reference drugs for triple combination test drug in Russia PharmCat 2019-11-16 17:22
- Reference drugs for triple combination test drug in Russia Beholder 2019-11-18 10:13
- Reference drugs for triple combination test drug in Russia PharmCat 2019-11-18 22:47
- WHO FDC Scenario 2 mittyri 2019-11-19 09:25
- WHO FDC Scenario 2 PharmCat 2019-11-19 23:42
- EEU FDC Scenario 5.3.2 mittyri 2019-11-20 11:32
- EEU FDC Scenario 5.3.2 PharmCat 2019-11-20 15:39
- EMA example mittyri 2019-11-21 12:38
- EEU FDC Scenario 5.3.2 PharmCat 2019-11-20 15:39
- EEU FDC Scenario 5.3.2 mittyri 2019-11-20 11:32
- WHO FDC Scenario 2 PharmCat 2019-11-19 23:42
- Reference drugs for triple combination test drug in Russia Beholder 2019-11-19 14:39
- Reference drugs for triple combination test drug in Russia Yura 2019-11-19 21:51
- Reference drugs for triple combination test drug in RussiaPharmCat 2019-11-21 14:02
- Reference drugs for triple combination test drug in Russia Yura 2019-11-19 21:51
- WHO FDC Scenario 2 mittyri 2019-11-19 09:25
- Reference drugs for triple combination test drug in Russia PharmCat 2019-11-18 22:47
- Reference drugs for triple combination test drug in Russia mittyri 2019-11-15 23:29
- Reference drugs for triple combination test drug in Russia Mikalai 2019-11-15 13:36
- Reference drugs for triple combination test drug in Russia Yura 2019-11-14 09:24
- Reference drugs for triple combination test drug in Russia PharmCat 2019-11-13 21:25